ProCE Banner Activity

Key Data From EHA 2021: A European Expert Perspective

Clinical Thought
Read this commentary where hematology experts from Europe share their thoughts on important results from key clinical trials on β-thalassemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and multiple myeloma presented at the virtual EHA 2021 meeting.

Released: July 28, 2021

Expiration: July 27, 2022

Share

Faculty

Charles Craddock

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci

Academic Director, Centre for Clinical Haematology
Chair, UK NCRI AML Working Party
University Hospitals Birmingham
Director, Blood and Marrow Transplant Unit
Professor of Haemato-oncology
University Hospitals Birmingham NHS Foundation Trust, UK
Birmingham, United Kingdom

Lydia Scarfò

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Ali T. Taher

Ali T. Taher, MD, PhD, FRCP

Professor of Medicine, Hematology and Oncology
Division of Hematology and Oncology
Department of Internal Medicine
American University of Beirut Medical Center
Beirut, Lebanon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Bristol Myers Squibb

Jazz Pharmaceuticals

Faculty Disclosure

Primary Author

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci

Academic Director, Centre for Clinical Haematology
Chair, UK NCRI AML Working Party
University Hospitals Birmingham
Director, Blood and Marrow Transplant Unit
Professor of Haemato-oncology
University Hospitals Birmingham NHS Foundation Trust, UK
Birmingham, United Kingdom

Prof. Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci, has disclosed that he has received consulting/advisory fees from AbbVie, Astellas, Bristol-Myers Squibb, Daiichi Sankyo, Eurocept, Janssen, Jazz, Kite, Novartis, Pfizer, and Roche; fees for non-CME/CE services from AbbVie, Astellas, Bristol-Myers Squibb, Daiichi Sankyo, Eurocept, Janssen, Novartis, Pfizer, and Roche; funds for research support from Jazz and Kite.

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Lydia Scarfò, MD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, and Janssen.

Ali T. Taher, MD, PhD, FRCP

Professor of Medicine, Hematology and Oncology
Division of Hematology and Oncology
Department of Internal Medicine
American University of Beirut Medical Center
Beirut, Lebanon

Ali T. Taher, MD, PhD, FRCP, has disclosed that he has received consulting fees from Agios, Bristol-Myers Squibb/Celgene, Ionis, Novartis, and Vifor and funds for research support from Bristol-Myers Squibb/Celgene, Ionis, Novartis, and Vifor.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.